European urology最新文献

{"title":"Re: Agne Krilaviciute, Nikolaus Becker, Sigrid V. Carlsson, et al. Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-aged Men - Data from the PROBASE Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.016.","authors":"Ola Bratt, Anna Lantz, Rebecka Arnsrud Godtman","doi":"10.1016/j.eururo.2026.08.022","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.022","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer.","authors":"Byuri Angela Cho, Curtis J Perry, Seong-Keun Yoo, Jacob Mercer, Christina Thai, Guru Sonpavde, Paul A Fields, Alan Tan, Daniel P Petrylak, Matthew D Galsky","doi":"10.1016/j.eururo.2026.08.005","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.005","url":null,"abstract":"<p><p>Enfortumab vedotin (EV) + pembrolizumab (P; EV + P) is the preferred first-line standard-of-care treatment for metastatic urothelial carcinoma (mUC), yet predictive biomarkers remain lacking. We retrospectively investigated whether tumor NECTIN4 RNA expression and tumor mutational burden (TMB) are associated with outcomes in a real-world mUC cohort receiving first-line EV + P (N = 322). NECTIN4-high subgroup showed more favorable overall survival (OS; hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.46-0.98; median 21.5 mo [95% CI 16.2-24.3] vs 14.2 mo [95% CI 12.6-23.8]) and best overall response (BOR; odds ratio [OR] 2.98, 95% CI 1.68-5.3; objective response rate [ORR]; 67.4% vs 41.9%) than NECTIN4-low subgroup. TMB-high subgroup also showed more favorable OS (HR 0.57, 95% CI 0.33-0.96; median 22.8 mo [95% CI 21.5 to not reached] vs 15.9 mo [95% CI 13.6-19.1]) and BOR (OR 2.26, 95% CI 1.14-4.47; ORR; 69.2% vs 52.6%) than TMB-low subgroup. In multivariable analyses, NECTIN4 expression independently predicted OS (adjusted HR 0.62, 95% CI 0.41-0.93) and BOR (adjusted OR 2.64, 95% CI 1.4-4.97). Patients with NECTIN4-high and/or TMB-high tumors had more favorable OS (HR 0.61, 95% CI 0.42-0.88) and BOR (OR 3.09, 95% CI 1.72-5.54) than those with double-low tumors. In contrast, NECTIN4 expression was not significantly associated with outcomes in the first-line P monotherapy cohort (N = 232). Overall, pretreatment tumor NECTIN4 RNA expression was associated with EV + P efficacy, with NECTIN4-low and TMB-low tumors showing the lowest likelihood of response.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Alexander Light, Max Peters, Archana Gopalakrishnan, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.05.007.","authors":"Drew T Bergman, Himanshu Nagar, Timothy D McClure","doi":"10.1016/j.eururo.2026.08.024","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.024","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 2026;395:338-48. doi:10.1056/NEJMoa2601486; and Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211-214. doi:10.1016/S1470-2045(10)70275-8.","authors":"Patrizia Giannatempo, Linda Cerbone, Fabio Calabrò","doi":"10.1016/j.eururo.2026.08.019","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.019","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149003200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.","authors":"Tarek Taha, Ossian Longoria, Johann de Bono","doi":"10.1016/j.eururo.2026.07.025","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.025","url":null,"abstract":"<p><p>Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing the risk of overinterpreting nontumour or nonactionable genomic alterations.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to T. Takahashi's Letter to the Editor re: Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press.","authors":"David-Dan Nguyen, Borna Tadayon Najafabadi, Laura C Rosella, Philipp Dahm, Gordon H Guyatt, Girish S Kulkarni","doi":"10.1016/j.eururo.2026.07.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.017","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.","authors":"Struan Gray, Peter Dutey-Magni, Craig Jones, Laura R Murphy, Macey L Murray, Janet E Brown, Eugene McCloskey, Mick Brown, Claire L Amos, Duncan C Gilbert, Robert J Jones, William Cross, David Matheson, Robin Millman, M K B Parmar, M R Sydes, L C Brown, G Attard, N D James, N W Clarke, A Sachdeva","doi":"10.1016/j.eururo.2026.08.012","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.012","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) patients are at increased fracture risk due to the need for androgen deprivation therapy (ADT) and progressive bone metastases. Previous meta-analyses of randomised controlled trials suggest that androgen receptor pathway inhibitors (ARPIs) increase fracture risk.</p><p><strong>Objective: </strong>We assessed the impact of abiraterone-based treatment intensification on fracture-related hospitalisation (FRH) within the STAMPEDE trial platform.</p><p><strong>Design, setting and participants: </strong>We performed a secondary analysis of two STAMPEDE trials in patients with high-risk non-metastatic (M0) or metastatic (M1) disease.</p><p><strong>Interventions: </strong>Patients were allocated to either standard of care (SOC) or SOC plus abiraterone with prednisolone (AAP) or, in a later comparison, SOC+AAP with enzalutamide (Enza).</p><p><strong>Outcome measurements and statistical analysis: </strong>A prespecified coding framework within Hospital Episode Statistics (HES) identified FRHs. Flexible parametric competing-risk models estimated 5-year cumulative incidence of FRH and sub-distribution hazard ratios (SDHR), with death as a competing risk.</p><p><strong>Outcome measurements and statistical analysis: </strong>Between Nov 2011 and Mar 2016, 3893 patients were randomised to the STAMPEDE AAP±Enza trials. Linked HES data were available for 3102 patients in England. In M1 disease, 5-year FRH incidence was significantly lower with SOC + AAP than SOC alone (22% vs 30%; SDHR 0.77, 95%CI 0.59-0.99; p = 0.04) and with SOC + AAP + Enza than SOC alone (28% vs 38%; SDHR 0.69, 95%CI 0.54-0.88; p = 0.002). No significant difference was observed in M0 patients. Limitations include potential under-estimation of total fracture burden by exclusion of non-hospitalised fractures, lack of baseline assessment of fracture risk including bone mineral density, and longitudinal use of bone-protective therapy.</p><p><strong>Conclusions: </strong>Abiraterone-based treatment intensification did not increase FRH compared to SOC alone. In M1 disease, abiraterone reduced rather than augmented fracture risk, most plausibly reflecting improved metastatic bone disease control.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148914775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Rana R. McKay, Karla V. Ballman, Pamela J. Atherton, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026;44:2341-52.","authors":"Giandomenico Roviello, Lorenzo Antonuzzo","doi":"10.1016/j.eururo.2026.08.016","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.016","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148908180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Alexander D. Sherry, Cara Haymaker, Shuqi Wang, et al. Addition of Metastasis-directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02856.","authors":"Paolo Zaurito, Giorgio Gandaglia, Francesco Montorsi","doi":"10.1016/j.eururo.2026.08.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.017","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.","authors":"Niyazi Volkan Demircan","doi":"10.1016/j.eururo.2026.08.011","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.011","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148883022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}